Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Opthamology’s Diverse Pipeline Could Rejuvenate Previously Stagnant Therapy Area

By Dominic Trewartha, Managing Analyst, GBI Research | September 19, 2016

The ophthalmology market has experienced relatively little advancement in recent years and, with large unmet needs remaining in this area, there are strong opportunities for more products to enter the treatment space, according to business intelligence provider GBI Research.

The company’s latest report states that scientific advancements in this therapy area – which includes glaucoma, age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy and dry eye syndrome – have revealed a broad range of novel potential molecular targets in recent decades, enabling progress in a previously stagnant field. This is reflected by the high number of products in development, with 782 products currently in the ophthalmology therapy pipeline.

The ophthalmology pipeline contains a diverse range of molecular targets and no single target dominates by any clear margin. However, products acting on components of the immune system – largely cytokine and cytokine receptors – and its regulatory signalling pathways make up the largest segment, followed by angiogenesis inhibitors.

A number of novel approaches are being tested across the major ophthalmology conditions, most notably wet and dry AMD, and glaucoma. There are a total of 158 first-in-class pipeline products in development for ophthalmology indications, representing 36% of the 438 pipeline products for which there is a disclosed molecular target.

Current first-in-class approaches to treatment, such as topical nerve growth factor application and slowing of the visual cycle, have being gaining significant traction in preclinical and clinical trials. They appear generally promising in terms of safety and efficacy, and have significant potential to strengthen the treatment landscape for key ophthalmological conditions by improving patient outcomes, as well as representing promising commercial opportunities.

With such promise in the pipeline, the ophthalmology deals landscape is highly active. Many products in the current pipeline have previously been involved in licensing and co-development deals.

These products act on a broad range of molecular targets, and consist of a range of molecule types. This indicates a strong degree of strategic consolidation uptake for first-in-class products in ophthalmology, and a willingness on the part of companies to invest in innovative products.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE